in the clinical day-to-day management of patients with primary hypothyroidism.
Currently, expert recommended target ranges for TSH in those receiving thyroxine is a very narrow range, between .5 and 2 milli-international units per liter. This reflects the approximation of the currently hypothesized normal TSH range that's seen in the majority of normal individuals. Thyrotropin suppressive therapy with thyroxine in thyroid cancer patients is also considered clinically very useful. Again, TSH is the recommended parameter to follow these patients, but here, the therapeutic window is much narrower.
Recent information indicates that the normal range observed over one year of monthly sampling is much narrower than the range suggested by observations of cross-sectional populations and therefore published in laboratories. In addition to this, each individual demonstrates a unique set point which is their own personal, far-narrower normal range as indicated by the skew between the patients here.
These observations led the investigators in this particular publication to postulate that TSH values,